FilingReader Intelligence
Shanghai Pharma drug wins approval for $200m market
July 21, 2025 at 08:40 AM UTC•By FilingReader AI
Shanghai Pharmaceuticals announced its subsidiary Shanghai SINE Tianping Gold & Red Pharmaceutical received approval for its tranexamic acid injection to pass generic drug quality and efficacy consistency evaluation.
The company invested approximately 342 million yuan in research and development for the bleeding treatment drug. The injectable tranexamic acid market in mainland Chinese hospitals was valued at 1.43 billion yuan in 2024, according to IQVIA data.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:601607•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Shanghai Pharmaceuticals Holding publishes news
Free account required • Unsubscribe anytime